PhoenixBio Co., Ltd. operates as a holding company that develops technologies for mass propagation of human cells into laboratory animals. Its solutions encompass PXB mouse services, Tg & KO animal services, and hair regeneration projects. It also offers its technologies to researchers by conducting in-house study services with custom produced transgenic animals. The company was founded on March 4, 2002 and is headquartered in Higashi-Hiroshima, Japan.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.

Yecuris™ is a technology development company obsessed with bringing novel tools to aid researchers in their search for cures. Our proprietary FRG® animal technologies have enabled breakthrough science in the areas of infectious disease, toxicology and metabolism—and we're just getting started. Explore our science and see how we can partner to accelerate your research.

Central Institute for Experimental Animals (CIEA) (実験動物中央研究所) is a research center for experimental animals in Japan. It was founded by Tatsuji Nomura in 1952 with the mission of improving the level of biomedical research.

Vesta Therapeutics, Inc. develops cell therapies for liver repair and regeneration. Its technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. The company was founded on October 21, 2002 and is headquartered in Hanover, MD.

Beijing Northland Biotech is a R&D high-tech enterprise mainly engaged in the development of therapeutic biological products.The company is a key high-tech enterprise of the National Torch Program, Beijing Science and Technology Research and Development Agency, Beijing Rare Plasmid Gene Therapy Drug Engineering Technology Research Center, and Beijing Biomedical Industry G20 Innovation Leading Enterprise with a registered capital of 112.167.676 million yuan. , stock code 430047.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Van Andel Institute provides biomedical research and education services. Its services include antibody production, spectral karyotyping, immunostaining and mouse modeling, animal imaging, computational biology, flow cytometry, germline modification and cytogenetics, mass spectrometry and proteomics, microarray technology, sequencing, vivarium, xenotransplantation and michigan animal consortium, as well as analytical, cellular and molecular microscopy services. The company was founded by Jay van Andel and Betty Van Andel in 1996 and is headquartered in Grand Rapids, MI.

Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumor cells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan.

In Vitro, Inc. provides biological research products and services used for the detection of chemical-biological interactions in connection with drug development and research. Its products include human liver microsomes which contain drug-metabolizing enzymes for pharmaceutical and biotech companies. The company was founded on November 30, 1990 by Paul Silber and is headquartered in Baltimore, MD.